ContraFect Corporation CFRX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

18/100

0/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

ContraFect Corporation (CFRX) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 17/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score

18/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

✗

未來

20/100

Analyst consensus

→ Forecast

✗

过去

25/100

→ Income

✗

健康

0/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

28/100

→ Income

✗

成长

15/100

→ Income

—

收入

N/A

No coverage

估值概览 — CFRX

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.00

EV/EBITDA0.0

每股数据

EPS (TTM)$-124.97

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2013	$-1,765.90	$0.00	$-23.62M	-
2014	$-3,088.00	$0.00	$-30.15M	-
2015	$-864.00	$0.00	$-25.12M	-
2016	$-680.00	$0.00	$-28.54M	-
2017	$-223.20	$0.00	$-15.52M	-
2018	$-396.35	$0.00	$-37.68M	-
2019	$-121.93	$0.00	$-12.63M	-
2020	$-98.36	$0.00	$-27.99M	-
2021	$14.90	$0.00	$6.85M	-
2022	$-124.97	$0.00	$-65.15M	-